Sequenta Pockets $13 Million to Diagnose, Monitor Immune Systems Going Awry

The age of the $1,000 genome is said to be fast approaching, and the growing availability of fast, cheap DNA sequencing is already paving the way not just for new avenues of academic research, but also for intriguing new diagnostic startups like San Francisco-based Sequenta.
Xconomy